ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0029

A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing

Joao Carlos Batista-Liz1, María Sebastián Mora-Gil2, Evan Troendle3, Oisin Cappa3, Maite Leonardo4, Ana Peñalba4, Luis mARTIN pENAGOS5, Ligia Gabrie-Rodriguez6, Rafael Gálvez Sánchez6, Jose Luis Callejas7, Belen Sevilla8, Diego de Argila9, Esther Vicente-Rabaneda9, Santos Castañeda10, David Simpson3, Ricardo Blanco11, Verónica Pulito Cueto1 and Raquel Lopez Mejias1, 1IDIVAL, Santander, Spain, 2Immunopathology Group, IDIVAL, Santander, Spain, 3Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, 4Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 7Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, 8Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 9Hospital Universitario de la Princesa, Madrid, Spain, 10Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 11Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Lymphocyte, Biomarkers, Gene Expression, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0019–0048) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined [1], the molecular mechanisms driving disease onset and progression remain poorly understood. Diagnosis still relies on invasive tissue biopsies, underscoring the need for molecular biomarkers to support non-invasive alternatives. Although B cells are central to IgA biology, their role in IgAV pathogenesis remains unclear [2], particularly regarding the regulation of IgA glycosylation [3]. Here, we present the first single-cell RNA sequencing (scRNA-seq) analysis of peripheral B cells in IgAV, with the aim to identify cell subpopulations presenting transcriptional alterations associated with the disease’s ethiopathogenesis.

Methods: For this study we recruited 12 Caucasian IgAV patients in the acute phase of the disease and 12 healthy individuals matched by sex, age, and ethnicity to the patients. From the extracted peripheral blood, mononuclear cells were isolated using a density gradient with Ficol and purified the CD19+ B Cells using a magnetic separation kit using MACS® Technology. Single-cell separation and library preparation was carried out using the Chromium platform (10X technologies) and Illumina library preparation kits. Transcriptomic sequencing was carried out on a Novaseq X plus instrument. Raw sequencing data was preprocessed with cellranger and its outputs were analysed with Scanpy and Seurat.

Results: Interestingly, our results reveal for the first time a B cell subpopulation significantly enriched in IgAV patients compared to healthy controls (Fig. 1A). This subset, corresponding to Leiden cluster 6, showed a marked overrepresentation in the IgAV group, as illustrated by both the cluster-wise proportion comparison (Fig. 1B) and the heatmap of cluster proportions (Fig. 1C). Of note, differential gene expression analysis of this population revealed dysregulation of key genes involved in O-glycosylation pathways (Fig. 2), including known regulators of IgA glycosylation. These findings suggest that this B cell subset may contribute to IgAV pathogenesis through the production of aberrantly glycosylated IgA, highlighting its potential relevance as both a mechanistic driver and a biomarker of disease.

Conclusion: Our results reveal, for the first time, a B cell subpopulation with dysregulated glycosylation genes characteristic of IgAV, highlighting its potential as a disease-specific biomarker and a contributor to pathogenic IgA production.References:[1] Arthritis Rheum. 2013 Jan;65(1):1-11. [2] Front Immunol. 2022 Oct 3:13:921864. [3] Semin Nephrol. 2024 Sep;44(5):151571.Funding: European Union FEDER funds and “Fondo de Investigaciones Sanitarias” from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), (PI21/00042 and PI24/00382 ). JCBL: PFIS program fellowship from the ISCIII, co-funded by the European Social Fund (`Investing in your future´), (FI22/00020), M-AES mobility grant (MV24/00004). RL-M: Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future” (CPII21/00004).

Supporting image 1Figure 1. A) UMAP visualization of B cell subpopulations identified by Leiden clustering in IgAV patients and healthy controls. The red arrow indicates the cluster of interest (Leiden cluster 6), which is enriched in IgAV samples. B) Stacked bar plot showing the relative proportions of B cell clusters in each group. Leiden cluster 6, highlighted with a red arrow and box, is overrepresented in IgAV patients. C) Heatmap summarizing B cell cluster proportions across individual samples, further illustrating the expansion of Leiden cluster 6 in IgAV.

Supporting image 2Figure 2. Volcano plot of differential gene expression from the B cell subpopulation identified in Leiden cluster 6. Genes highlighted in red are associated with glycosylation pathways implicated in the production of aberrantly glycosylated IgA. Dotted line represents a 0.05 p-value threshold.


Disclosures: J. Batista-Liz: None; M. Sebastián Mora-Gil: None; E. Troendle: None; O. Cappa: None; M. Leonardo: None; A. Peñalba: None; L. mARTIN pENAGOS: None; L. Gabrie-Rodriguez: None; R. Gálvez Sánchez: None; J. Callejas: None; B. Sevilla: None; D. de Argila: None; E. Vicente-Rabaneda: None; S. Castañeda: None; D. Simpson: None; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6; V. Pulito Cueto: None; R. Lopez Mejias: None.

To cite this abstract in AMA style:

Batista-Liz J, Sebastián Mora-Gil M, Troendle E, Cappa O, Leonardo M, Peñalba A, mARTIN pENAGOS L, Gabrie-Rodriguez L, Gálvez Sánchez R, Callejas J, Sevilla B, de Argila D, Vicente-Rabaneda E, Castañeda S, Simpson D, Blanco R, Pulito Cueto V, Lopez Mejias R. A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-novel-b-cell-subpopulation-characteristic-of-iga-vasculitis-identified-by-single-cell-rna-sequencing/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-b-cell-subpopulation-characteristic-of-iga-vasculitis-identified-by-single-cell-rna-sequencing/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology